| Symbol | ARVN |
|---|---|
| Name | ARVINAS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 395 WINCHESTER AVENUE,5 SCIENCE PARK, NEW HAVEN, Connecticut, 06511, United States |
| Telephone | +1 203 535-1456 |
| Fax | — |
| — | |
| Website | https://www.arvinas.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001655759 |
| Description | Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The companys proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cells own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases. The groups product candidates are bavdegalutamide, ARV-471 and ARV-766. Additional info from NASDAQ: |
2026-06-24 21:20
Saik Andrew 🔴 sold 5.7K shares of ARVINAS, INC. (ARVN) at $8.16 Transaction Date: Jun 24, 2026 | Filing ID: 045286
Read more
2026-06-23 22:09
📋 Andrew Saik (Officer) plans to sell 6K shares of Arvinas Inc (at $8.14 each, total $48K) Filed: Jun 23, 2026 | ID: 044980
Read more
2026-06-17 12:59
📋 Angela Cacace (Officer) plans to sell 3K shares of Arvinas Inc (at $7.42 each, total $20K) Filed: Jun 17, 2026 | ID: 043732
Read more
2026-06-04 12:00
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
Read more
2026-05-22 20:15
Director Teel Randy 🔴 sold 2.2K shares of ARVINAS, INC. (ARVN) at $9.04 Transaction Date: May 21, 2026 | Filing ID: 037728
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07231991 | A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant… | Phase1 | Healthy Participants | Recruiting | 2025-11-18 | 2026-12-23 | ClinicalTrials.gov |
| NCT07023731 | A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G1… | Phase1 | KRAS G12D Mutation | Active_Not_Recruiting | 2025-05-29 | 2029-04-02 | ClinicalTrials.gov |
| NCT06911788 | A Study to Learn How a Tablet Compared With an IV Infusion of the Study Medicin… | Phase1 | Healthy Participants | Completed | 2025-04-03 | 2025-06-13 | ClinicalTrials.gov |
| NCT06645938 | A Study to Learn How Different Tablets of the Study Medicine Vepdegestrant Are … | Phase1 | Healthy | Completed | 2024-10-16 | 2025-03-14 | ClinicalTrials.gov |
| NCT06393738 | A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. | Phase1 | Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) | Recruiting | 2024-09-05 | 2028-03-01 | ClinicalTrials.gov |
| NCT06347861 | A Study to Learn How Various Tablets of the Study Medicine Vepdegestrant Are Ta… | Phase1 | Healthy | Completed | 2024-04-02 | 2024-08-08 | ClinicalTrials.gov |
| NCT06275841 | A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Proces… | Phase1 | Healthy | Completed | 2024-02-23 | 2024-05-24 | ClinicalTrials.gov |
| NCT06206837 | A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With… | Phase1 | Breast Cancer | Active_Not_Recruiting | 2024-02-19 | 2026-09-07 | ClinicalTrials.gov |
| NCT06256510 | A Study to Learn If the Study Medicine Called Vepdegestrant Changes How the Bod… | Phase1 | Healthy Participants | Completed | 2024-02-08 | 2024-05-13 | ClinicalTrials.gov |
| NCT06125522 | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given… | Phase1 | Breast Cancer | Active_Not_Recruiting | 2024-01-10 | 2026-12-31 | ClinicalTrials.gov |
| NCT06005688 | A Study to Understand the Effects of Carbamazepine on How Vepdegestrant is Proc… | Phase1 | Healthy Participants | Completed | 2023-08-18 | 2023-11-21 | ClinicalTrials.gov |
| NCT05909397 | Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in… | Phase3 | Breast Cancer | Active_Not_Recruiting | 2023-08-09 | 2026-12-30 | ClinicalTrials.gov |
| NCT05654623 | A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-0785032… | Phase3 | Advanced Breast Cancer | Active_Not_Recruiting | 2023-03-03 | 2028-05-15 | ClinicalTrials.gov |
| NCT05573555 | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given… | Phase1 | Breast Cancer | Active_Not_Recruiting | 2023-03-01 | 2026-12-30 | ClinicalTrials.gov |
| NCT05538312 | A Study to Understand the Effect of Itraconazole on the Levels of a Study Medic… | Phase1 | Healthy | Completed | 2023-02-23 | 2023-05-22 | ClinicalTrials.gov |
| NCT05548127 | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given… | Phase1 | Breast Cancer | Active_Not_Recruiting | 2023-02-23 | 2026-09-01 | ClinicalTrials.gov |
| NCT05732428 | A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-078… | Phase1 | Breast Cancer | Completed | 2023-02-20 | 2024-11-01 | ClinicalTrials.gov |
| NCT05549505 | A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cance… | Phase2 | Breast Cancer | Completed | 2023-02-15 | 2024-07-25 | ClinicalTrials.gov |
| NCT05673889 | A Study to Understand the Effect of a Study Medicine Called ARV-471 on Dabigatr… | Phase1 | Healthy | Completed | 2023-01-27 | 2023-04-19 | ClinicalTrials.gov |
| NCT05652660 | A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvast… | Phase1 | Healthy | Completed | 2022-12-09 | 2023-03-06 | ClinicalTrials.gov |
| NCT05501769 | ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metasta… | Phase1 | Breast Cancer | Completed | 2022-09-08 | 2025-08-25 | ClinicalTrials.gov |
| NCT05463952 | A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With … | Phase1 | Breast Neoplasms | Active_Not_Recruiting | 2022-08-16 | 2025-03-31 | ClinicalTrials.gov |
| NCT05177042 | Trial of ARV-110 and Abiraterone in Participants With Metastatic Prostate Cancer | Phase1 | Prostate Cancer Metastatic | Completed | 2022-05-13 | 2025-04-10 | ClinicalTrials.gov |
| NCT04072952 | A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE… | Phase1 | Breast Cancer | Completed | 2019-08-05 | 2026-03-05 | ClinicalTrials.gov |
| NCT03888612 | Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Canc… | Phase1 | Prostate Cancer Metastatic | Completed | 2019-03-01 | 2025-01-27 | ClinicalTrials.gov |
Total clinical trials: 25
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| ARV-806 | Other | Phase PHASE1 | KRAS G12D Mutation | ACTIVE_NOT_RECRUITING | NCT07023731 |
| Samuraciclib | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06125522 |
| vepdegestrant | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06125522 |
| Samuraciclib | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06125522 |
| vepdegestrant | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06125522 |
| Samuraciclib | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06125522 |
| vepdegestrant | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06125522 |
| Samuraciclib | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06125522 |
| vepdegestrant | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06125522 |
| Samuraciclib | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06125522 |
| vepdegestrant | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06125522 |
| Samuraciclib | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06125522 |
| vepdegestrant | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06125522 |
| Samuraciclib | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06125522 |
| vepdegestrant | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06125522 |
| Samuraciclib | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06125522 |
| vepdegestrant | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06125522 |
| vepdegestrant | Other | Phase PHASE1 | Breast Neoplasms | ACTIVE_NOT_RECRUITING | NCT05463952 |
| vepdegestrant | Other | Phase PHASE1 | Breast Neoplasms | ACTIVE_NOT_RECRUITING | NCT05463952 |
| vepdegestrant | Other | Phase PHASE1 | Breast Neoplasms | ACTIVE_NOT_RECRUITING | NCT05463952 |
| [oxoisoindolin-14C]ARV-471 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05930925 |
| [phenyl-14C]ARV-471 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05930925 |
| [oxoisoindolin-14C]ARV-471 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05930925 |
| [phenyl-14C]ARV-471 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05930925 |
| Carbamazepine | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06005688 |
| Vepdegestrant | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06005688 |
| Carbamazepine | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06005688 |
| Vepdegestrant | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06005688 |
| esomeprazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT06275841 |
| vepdegestrant | Other | Phase PHASE1 | Healthy | COMPLETED | NCT06275841 |
| esomeprazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT06275841 |
| vepdegestrant | Other | Phase PHASE1 | Healthy | COMPLETED | NCT06275841 |
| Rosuvastatin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05652660 |
| ARV-471 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05652660 |
| Rosuvastatin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05652660 |
| ARV-471 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05652660 |
| Dabigatran etexilate | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05673889 |
| ARV-471 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05673889 |
| Dabigatran etexilate | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05673889 |
| ARV-471 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05673889 |
| Dabigatran etexilate | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05673889 |
| ARV-471 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05673889 |
| Itraconazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05538312 |
| vepdegestrant | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05538312 |
| Itraconazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05538312 |
| vepdegestrant | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05538312 |
| single dose of vepdegestrant as tablet formulation (Treatment C) | Drug | Phase PHASE1 | Healthy | COMPLETED | NCT06347861 |
| single dose of vepdegestrant as tablet formulation (Treatment B) | Drug | Phase PHASE1 | Healthy | COMPLETED | NCT06347861 |
| single dose of vepdegestrant as tablet formulation (Treatment A) | Drug | Phase PHASE1 | Healthy | COMPLETED | NCT06347861 |
| Vepdegestrant | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06256510 |
| Midazolam | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06256510 |
| Vepdegestrant | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06256510 |
| Midazolam | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06256510 |
| Vepdegestrant | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06256510 |
| Midazolam | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06256510 |
| ARV-471 | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT05732428 |
| ARV-471 | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT05732428 |
| ARV-471 | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT05732428 |
| ARV-110 | Other | Phase PHASE1 | Prostate Cancer Metastatic | COMPLETED | NCT03888612 |
| single dose of vepdegestrant as tablet formulation (Treatment B) | Drug | Phase PHASE1 | Healthy | COMPLETED | NCT06645938 |
| single dose of vepdegestrant as tablet formulation (Treatment A) | Drug | Phase PHASE1 | Healthy | COMPLETED | NCT06645938 |
| single dose of vepdegestrant as tablet formulation (Treatment B) | Drug | Phase PHASE1 | Healthy | COMPLETED | NCT06645938 |
| single dose of vepdegestrant as tablet formulation (Treatment A) | Drug | Phase PHASE1 | Healthy | COMPLETED | NCT06645938 |
| Vepdegestrant (Test) | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06911788 |
| Vepdegestrant (Reference) | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06911788 |
| Vepdegestrant (Test) | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06911788 |
| Vepdegestrant (Reference) | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06911788 |
| ARV-110 in Combination with Abiraterone | Other | Phase PHASE1 | Prostate Cancer Metastatic | COMPLETED | NCT05177042 |
| ARV-110 in Combination with Abiraterone | Other | Phase PHASE1 | Prostate Cancer Metastatic | COMPLETED | NCT05177042 |
| Surgical resection of breast tumor | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT05549505 |
| Anastrozole | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT05549505 |
| ARV-471 | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT05549505 |
| Letrozole | Other | Phase PHASE3 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05909397 |
| Palbociclib | Other | Phase PHASE3 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05909397 |
| Vepdegestrant (ARV-471/PF-07850327) | Other | Phase PHASE3 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05909397 |
| Letrozole | Other | Phase PHASE3 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05909397 |
| Palbociclib | Other | Phase PHASE3 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05909397 |
| Vepdegestrant (ARV-471/PF-07850327) | Other | Phase PHASE3 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05909397 |
| Letrozole | Other | Phase PHASE3 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05909397 |
| Palbociclib | Other | Phase PHASE3 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05909397 |
| Vepdegestrant (ARV-471/PF-07850327) | Other | Phase PHASE3 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05909397 |
| ARV-806 | Other | Phase PHASE1 | KRAS G12D Mutation | RECRUITING | NCT07023731 |
| ARV-471 in combination with Everolimus | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT05501769 |
| Samuraciclib | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06125522 |
| vepdegestrant | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06125522 |
| Samuraciclib | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06125522 |
| vepdegestrant | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06125522 |
| Samuraciclib | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06125522 |
| vepdegestrant | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06125522 |
| Glofitamab | Other | Phase PHASE1 | Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) | RECRUITING | NCT06393738 |
| ARV-393 | Other | Phase PHASE1 | Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) | RECRUITING | NCT06393738 |
| Abemaciclib | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05548127 |
| ARV-471 | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05548127 |
| PF-07220060 | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06206837 |
| vepdegestrant | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06206837 |
| PF-07220060 | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06206837 |
| vepdegestrant | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06206837 |
| Ribociclib | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05573555 |
| ARV-471 | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05573555 |
| Ribociclib | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05573555 |
| ARV-471 | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05573555 |
| Fulvestrant | Other | Phase PHASE3 | Advanced Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05654623 |
| ARV-471 | Other | Phase PHASE3 | Advanced Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05654623 |
| Fulvestrant | Other | Phase PHASE3 | Advanced Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05654623 |
| ARV-471 | Other | Phase PHASE3 | Advanced Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05654623 |
| vepdegestrant | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07231991 |
| vepdegestrant | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07231991 |
| vepdegestrant | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07231991 |
| ARV-471 in combination with palbociclib (IBRANCE®) | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT04072952 |
| ARV-471 | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT04072952 |
| ARV-471 in combination with palbociclib (IBRANCE®) | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT04072952 |
| ARV-471 | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT04072952 |
| Abiraterone | Other | Phase PHASE1 | Prostate Cancer Metastatic | COMPLETED | NCT05177042 |
| Bavdegalutamide | Other | Phase PHASE1 | Prostate Cancer Metastatic | COMPLETED | NCT05177042 |
| Abiraterone | Other | Phase PHASE1 | Prostate Cancer Metastatic | COMPLETED | NCT05177042 |
| Bavdegalutamide | Other | Phase PHASE1 | Prostate Cancer Metastatic | COMPLETED | NCT05177042 |
| Abiraterone | Other | Phase PHASE1 | Prostate Cancer Metastatic | COMPLETED | NCT05177042 |
| Bavdegalutamide | Other | Phase PHASE1 | Prostate Cancer Metastatic | COMPLETED | NCT05177042 |
| Abiraterone | Other | Phase PHASE1 | Prostate Cancer Metastatic | COMPLETED | NCT05177042 |
| Bavdegalutamide | Other | Phase PHASE1 | Prostate Cancer Metastatic | COMPLETED | NCT05177042 |
| Abiraterone | Other | Phase PHASE1 | Prostate Cancer Metastatic | COMPLETED | NCT05177042 |
| Bavdegalutamide | Other | Phase PHASE1 | Prostate Cancer Metastatic | COMPLETED | NCT05177042 |
| Abiraterone | Other | Phase PHASE1 | Prostate Cancer Metastatic | COMPLETED | NCT05177042 |
| Bavdegalutamide | Other | Phase PHASE1 | Prostate Cancer Metastatic | COMPLETED | NCT05177042 |
| Abiraterone | Other | Phase PHASE1 | Prostate Cancer Metastatic | COMPLETED | NCT05177042 |
| Bavdegalutamide | Other | Phase PHASE1 | Prostate Cancer Metastatic | COMPLETED | NCT05177042 |
| Abiraterone | Other | Phase PHASE1 | Prostate Cancer Metastatic | COMPLETED | NCT05177042 |
| Bavdegalutamide | Other | Phase PHASE1 | Prostate Cancer Metastatic | COMPLETED | NCT05177042 |
| Abiraterone | Other | Phase PHASE1 | Prostate Cancer Metastatic | COMPLETED | NCT05177042 |
| Bavdegalutamide | Other | Phase PHASE1 | Prostate Cancer Metastatic | COMPLETED | NCT05177042 |
| Abiraterone | Other | Phase PHASE1 | Prostate Cancer Metastatic | COMPLETED | NCT05177042 |
| Bavdegalutamide | Other | Phase PHASE1 | Prostate Cancer Metastatic | COMPLETED | NCT05177042 |
| Dabigatran etexilate | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05673889 |
| ARV-471 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05673889 |
| Fulvestrant | DRUG | Phase PHASE3 | Advanced Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05654623 |
| ARV-471 | DRUG | Phase PHASE3 | Advanced Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05654623 |
| [oxoisoindolin-14C]ARV-471 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05930925 |
| [phenyl-14C]ARV-471 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05930925 |
| Carbamazepine | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06005688 |
| esomeprazole | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT06275841 |
| Rosuvastatin | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05652660 |
| Itraconazole | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05538312 |
| single dose of vepdegestrant as tablet formulation (Treatment C) | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT06347861 |
| Vepdegestrant | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06005688 |
| Midazolam | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06256510 |
| single dose of vepdegestrant as tablet formulation (Treatment B) | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT06347861 |
| single dose of vepdegestrant as tablet formulation (Treatment A) | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT06347861 |
| Vepdegestrant (Test) | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06911788 |
| Vepdegestrant (Reference) | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06911788 |
| ARV-110 in Combination with Abiraterone | DRUG | Phase PHASE1 | Prostate Cancer Metastatic | COMPLETED | NCT05177042 |
| ARV-471 in combination with Everolimus | DRUG | Phase PHASE1 | Breast Cancer | COMPLETED | NCT05501769 |
| Samuraciclib | DRUG | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06125522 |
| Letrozole | DRUG | Phase PHASE3 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05909397 |
| Vepdegestrant (ARV-471/PF-07850327) | DRUG | Phase PHASE3 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05909397 |
| Abemaciclib | DRUG | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05548127 |
| ARV-471 in combination with palbociclib (IBRANCE®) | DRUG | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04072952 |
| PF-07220060 | DRUG | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06206837 |
| Ribociclib | DRUG | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05573555 |
| vepdegestrant | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT06275841 |
| ARV-806 | DRUG | Phase PHASE1 | KRAS G12D Mutation | RECRUITING | NCT07023731 |
| Glofitamab | DRUG | Phase PHASE1 | Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) | RECRUITING | NCT06393738 |
| ARV-393 | DRUG | Phase PHASE1 | Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) | RECRUITING | NCT06393738 |
| Surgical resection of breast tumor | PROCEDURE | Phase PHASE2 | Breast Cancer | COMPLETED | NCT05549505 |
| Anastrozole | DRUG | Phase PHASE2 | Breast Cancer | COMPLETED | NCT05549505 |
| ARV-471 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05652660 |
| ARV-110 | DRUG | Phase PHASE1 | Prostate Cancer Metastatic | COMPLETED | NCT03888612 |
Total products: 166